Skip to content

Study of the Collaborative Life Skills Program

Efficacy of the Collaborative Life Skills Program

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01686724
Enrollment
504
Registered
2012-09-18
Start date
2012-09-30
Completion date
2016-06-30
Last updated
2019-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder Symptoms

Keywords

Attention Deficit Hyperactivity Disorder, Psychosocial Intervention, Behavioral Intervention, School-home collaborative intervention

Brief summary

This study tests the effectiveness of a newly developed integrated school-home behavioral intervention for behaviors related to Attention Deficit Hyperactivity Disorder (ADHD). The intervention is implemented by school-based mental health professionals within school settings.

Interventions

BEHAVIORALCollaborative Life Skills Intervention (CLS)

CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* Attending a participating school and in 2-5th grade * Referral by LSP as a child with apparent ADHD-related problems * ≥ 6 symptoms (item score ≥ 2) of Inattention or Hyperactivity-Impulsivity on the pooled parent and teacher Child Symptom Inventory * ≥ 3 on the Impairment Rating Scale by parent and teacher (cross-situational impairment) * FSIQ or VIQ ≥ 80 (necessary for cognitive demands of the child skills curriculum) * Caretaker consents to participate in treatment, child assents to participate

Exclusion criteria

* Presence of conditions that are incompatible with this study's treatment. * severe visual or hearing impairment, * severe language delay, * psychosis, * pervasive developmental disorder * Parent or child does not read or speak English or does not read or speak Spanish for our Spanish language implementation of CLS (inability to complete assessment measures or participate in group treatments). * Child is in an all-day special education classroom (children in these classrooms are frequently receiving intensive behavior modification programs such that the intervention would be expected to require modification for use in these settings) * Children taking psychotropic medication for any reason other than to treat ADHD * Children planning to change (start or stop) psychotropic medication * Children who have changed a regimen of psychotropic medication (started or stopped) within 30 days prior to screening

Design outcomes

Primary

MeasureTime frame
Symptoms of Attention Deficit Hyperactivity Disorder as defined by DSMIV/V.change from baseline on ADHD symptoms at 12 weeks

Secondary

MeasureTime frame
Academic Competency Evaluation Scale (ACES)change from baseline in ACES at 12 weeks
Children's Organizational Skills Scale (COSS)change from baseline in COSS at 12 weeks
Observations of classroom/school behaviorchange from baseline on observed on-task behavior at 12 weeks
Academic achievementchange from baseline in academic achievement at 12 weeks
Homework Problems Checklist (HPC)change from baseline in homework problems at 12 weeks
Social Skills Improvement Scalechange from baseline in social/behavioral functioning at 12 weeks
Test of Life Skills Knowledgechange from baseline in life skills knowledge at 12 weeks
Alabama Parenting Questionnairechange from baseline in parenting practices at 12 weeks
Parenting Stress Indexchange from baseline in parenting stress at 12 weeks
Academic Achievementchange from baseline in academic achievement at 7 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026